spacer
home > > spring 2009 > non-clinical acceleration
PUBLICATIONS


Non-Clinical Acceleration

In the course of the development of a new drug, the selection of the most promising molecule from a series of closely related molecules for further development is timeconsuming and expensive. Data provided by pharmacodynamic studies conducted in vitro or in vivo, or by pharmacological studies in test animals, are often inadequate to differentiate with sufficient reliability those molecules which should be excluded from further development. When considering start-up and smaller companies in particular, it is extremely important to focus as early as possible on the most promising candidate for further development, in order to save time, resources and costs.

In such a case, it must be emphasised that the most reliable information about a drug can really only be generated using human subjects (volunteers or patients). The results obtained when going first time in man are therefore of pivotal relevance, and enable a sponsor to get a much more accurate picture of the pharmacological potential of a molecule.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Ruediger Haecker is a qualified physician, specialising in biochemistry. He completed his academic education in Leipzig and Magdeburg, and has held academic positions as a Lecturer and Full Professor of Biochemistry in Dresden and Leipzig, Germany. Since 1990, Ruediger has held several positions researching the developments of human and veterinary pharmaceuticals. He has worked on around 30 scientific publications and written more than 150 papers and presentations. Ruediger joined Harlan Laboratories Ltd in 2001, working as a Scientific Advisor in non-clinical development, specialising in international drug regulatory affairs.

Steve Dean has a background in genetics and cell biology, and holds a PhD in oncology from the Paterson Laboratories in Manchester, UK. Following postdoctoral work both in the US and the UK, he began his industrial career as a Genetic Toxicologist at Covance, holding positions as Head of Genetic Toxicology and managing Toxicology Operations in Harrogate. In 1999 he took the opportunity to work in Italy as Managing Director of RTC in Rome, then returned in 2002 to the UK as Group Sales Director for HLS in Cambridgshire. In recent years he has continued to participate in scientific activities, is a past President of the UK Environmental Mutagen Society and a Eurotox-registered toxicologist. He recently relocated to Switzerland as Director of Business Development for Harlan Laboratories CRS Division.

spacer
Ruediger Haecker
spacer
spacer
spacer
Steve Dean
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Evolution Summit Press Release

“Many clinical trials today face delays because of difficulties in recruiting the required number of patients within the timeline. Sponsors need to look at other regions outside the US and Western Europe, that have access to a large pool of motivated patients, without compromising quality or anything else,” says Roman Hrynchuk, Chief Operating Officer, SanaClis. SanaClis was a solution provider at the Marcus Evans Evolution Summit March 2020.
More info >>

White Papers

Sterile Vials Made of Tubular Glass

Gerresheimer AG

Gx® RTF vials powered by Ompi EZ-fill® enhance flexibility by facilitating packaging needs from clinical stage to industrialization with the common goal to minimize customer product risks and optimize total cost of ownership. Gerresheimer combines the competencies in converting glass tubes to serum/ injection vials and ready-to-fill processing for our pharma and biotech customers.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement